<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20241014224556&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20241014224556&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 15 Oct 2024 02:45:58 +0000</lastbuilddate>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Patients With Advanced Heart Failure and Atrial Fibrillation Deserve an Attempt at Catheter Ablation as First-Line Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39401282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 15;150(16):1220-1222. doi: 10.1161/CIRCULATIONAHA.124.069759. Epub 2024 Oct 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39401282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39401282</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069759>10.1161/CIRCULATIONAHA.124.069759</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39401282</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Christian Sohns</dc:creator>
<dc:creator>Philipp Sommer</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Patients With Advanced Heart Failure and Atrial Fibrillation Deserve an Attempt at Catheter Ablation as First-Line Therapy</dc:title>
<dc:identifier>pmid:39401282</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069759</dc:identifier>
</item>
<item>
<title>Pathogenesis of Atherothrombotic Events: From Lumen to Lesion and Beyond</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39401281/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 15;150(16):1217-1219. doi: 10.1161/CIRCULATIONAHA.124.070087. Epub 2024 Oct 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39401281/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39401281</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070087>10.1161/CIRCULATIONAHA.124.070087</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39401281</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter Libby</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Pathogenesis of Atherothrombotic Events: From Lumen to Lesion and Beyond</dc:title>
<dc:identifier>pmid:39401281</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070087</dc:identifier>
</item>
<item>
<title>Response by Hoedemakers et al to Letter Regarding Article, "mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39401280/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 15;150(16):e278-e279. doi: 10.1161/CIRCULATIONAHA.124.071022. Epub 2024 Oct 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39401280/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39401280</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071022>10.1161/CIRCULATIONAHA.124.071022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39401280</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarah Hoedemakers</dc:creator>
<dc:creator>Bernard Cosyns</dc:creator>
<dc:creator>Steven Droogmans</dc:creator>
<dc:creator>Frederik H Verbrugge</dc:creator>
<dc:creator>Lieven Herbots</dc:creator>
<dc:creator>Jan Verwerft</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Hoedemakers et al to Letter Regarding Article, "mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis"</dc:title>
<dc:identifier>pmid:39401280</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071022</dc:identifier>
</item>
<item>
<title>Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39401279/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. However, as more weight loss is achieved, there is concern for potential adverse effects on muscle quantity, composition, and function. This primer aims to address whether muscle-related changes associated with weight loss treatments such as GLP-1 RAs may be maladaptive (ie, adversely affecting muscle health...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 15;150(16):1288-1298. doi: 10.1161/CIRCULATIONAHA.124.067676. Epub 2024 Oct 14.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. However, as more weight loss is achieved, there is concern for potential adverse effects on muscle quantity, composition, and function. This primer aims to address whether muscle-related changes associated with weight loss treatments such as GLP-1 RAs may be maladaptive (ie, adversely affecting muscle health or function), adaptive (ie, a physiologic response to weight loss maintaining or minimally affecting muscle health or function), or perhaps an enhanced response to weight loss (ie, improved muscle health or function after treatment). Based on contemporary evidence with the addition of studies using magnetic resonance imaging, skeletal muscle changes with GLP-1 RA treatments appear to be adaptive: changes in muscle volume z-score indicate a change in muscle volume that is commensurate with what is expected given aging, disease status, and weight loss achieved, and the improvement in insulin sensitivity and muscle fat infiltration likely contributes to an adaptive process with improved muscle quality, lowering the probability for loss in strength and function. Nevertheless, factors such as older age and prefrailty may influence the selection of appropriate candidates for these therapies because of risk for sarcopenia. Several pharmacologic treatments to maintain or improve muscle mass designed in combination with GLP-1-based therapies are under development. For future development of GLP-1-based therapies (and other therapies) designed for weight loss, as well as for patient-centered treatment optimization, the introduction of more objective and comprehensive ways of assessing muscle health (including accurate and meaningful assessments of muscle quantity, composition, function, mobility, and strength) is important for the substantial numbers of patients who will likely be taking these medications well into the future.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39401279/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39401279</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.067676>10.1161/CIRCULATIONAHA.124.067676</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39401279</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer Linge</dc:creator>
<dc:creator>Andreas L Birkenfeld</dc:creator>
<dc:creator>Ian J Neeland</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?</dc:title>
<dc:identifier>pmid:39401279</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.067676</dc:identifier>
</item>
<item>
<title>Sustained but Decoyed Activation of the JAK1-STAT Pathway by Aberrant Protein Aggregation Exacerbates Proteotoxicity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39401278/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 15;150(16):1302-1305. doi: 10.1161/CIRCULATIONAHA.124.070067. Epub 2024 Oct 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39401278/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39401278</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070067>10.1161/CIRCULATIONAHA.124.070067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39401278</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Mingqi Cai</dc:creator>
<dc:creator>Bo Pan</dc:creator>
<dc:creator>Peng Xiao</dc:creator>
<dc:creator>Mark Bouska</dc:creator>
<dc:creator>Megan T Lewno</dc:creator>
<dc:creator>Yu Xing</dc:creator>
<dc:creator>Erliang Zeng</dc:creator>
<dc:creator>Huiyun Liang</dc:creator>
<dc:creator>Faqian Li</dc:creator>
<dc:creator>Xiang Gao</dc:creator>
<dc:creator>Xuejun Wang</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Sustained but Decoyed Activation of the JAK1-STAT Pathway by Aberrant Protein Aggregation Exacerbates Proteotoxicity</dc:title>
<dc:identifier>pmid:39401278</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070067</dc:identifier>
</item>
<item>
<title>Optical Spectroscopic Detection and Typing of Cardiac Amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39401277/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 15;150(16):1299-1301. doi: 10.1161/CIRCULATIONAHA.124.069554. Epub 2024 Oct 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39401277/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39401277</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069554>10.1161/CIRCULATIONAHA.124.069554</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39401277</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sudipta S Mukherjee</dc:creator>
<dc:creator>Joseph J Maleszewski</dc:creator>
<dc:creator>Daniel Luthringer</dc:creator>
<dc:creator>Matthew P Confer</dc:creator>
<dc:creator>Anirudh Mittal</dc:creator>
<dc:creator>Surendra Dasari</dc:creator>
<dc:creator>Ellen D McPhail</dc:creator>
<dc:creator>Suraj Kapa</dc:creator>
<dc:creator>Thenkurussi Kesavadas</dc:creator>
<dc:creator>Andre Kajdacsy-Balla</dc:creator>
<dc:creator>Evan Kransdorf</dc:creator>
<dc:creator>Jai Raman</dc:creator>
<dc:creator>Rohit Bhargava</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Optical Spectroscopic Detection and Typing of Cardiac Amyloidosis</dc:title>
<dc:identifier>pmid:39401277</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069554</dc:identifier>
</item>
<item>
<title>Letter by Jha Regarding Article, "mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39401276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 15;150(16):e276-e277. doi: 10.1161/CIRCULATIONAHA.124.070147. Epub 2024 Oct 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39401276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39401276</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070147>10.1161/CIRCULATIONAHA.124.070147</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39401276</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ajay Kumar Jha</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Jha Regarding Article, "mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis"</dc:title>
<dc:identifier>pmid:39401276</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070147</dc:identifier>
</item>
<item>
<title>Focus on ischaemic heart disease: secondary prevention, cardiogenic shock, and novel therapeutic targets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39400274/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 14;45(39):4141-4144. doi: 10.1093/eurheartj/ehae689.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39400274/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39400274</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae689>10.1093/eurheartj/ehae689</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39400274</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on ischaemic heart disease: secondary prevention, cardiogenic shock, and novel therapeutic targets</dc:title>
<dc:identifier>pmid:39400274</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae689</dc:identifier>
</item>
<item>
<title>Plasma proteome and incident myocardial infarction: sex-specific differences</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39397782/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study identified both new and confirmed previously established associations between circulating proteins and incident MI and, for the first time, suggested sex-specific patterns in multiple protein-MI associations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 14:ehae658. doi: 10.1093/eurheartj/ehae658. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Few population-based cohort studies, including both men and women, have explored circulating proteins associated with incident myocardial infarction (MI). This study investigated the relationships between circulating cardiometabolic-related proteins and MI risk using cohort-based and Mendelian randomization (MR) analyses and explored potential sex-specific differences.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The discovery cohort included 11 751 Swedish adults (55-93 years). Data on 259 proteins assessed with Olink proximity extension assays, biochemical, and questionnaire-based information were used. Participants were followed up for incident MI and death over 8 years through linkage to Swedish registers. Replication analyses were conducted on the UK Biobank sample (n = 51 613). In MR analyses, index cis-genetic variants strongly related to the proteins were used as instrumental variables. Genetic association summary statistic data for MI were obtained from the CARDIoGRAMplusC4D consortium and FinnGen.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Forty-five proteins were associated with incident MI in discovery and replication samples following adjustment for potential confounders and multiple testing. In the secondary analysis, 13 of the protein associations were sex-specific, with most associations identified among women. In MR analysis, genetically predicted higher levels of renin, follistatin, and retinoic acid receptor responder protein 2 were linked to an increased risk of MI. Tissue factor pathway inhibitor, tumor necrosis factor receptors 1 and 2, placenta growth factor had an inverse association with MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study identified both new and confirmed previously established associations between circulating proteins and incident MI and, for the first time, suggested sex-specific patterns in multiple protein-MI associations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39397782/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39397782</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae658>10.1093/eurheartj/ehae658</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39397782</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Olga E Titova</dc:creator>
<dc:creator>Shuai Yuan</dc:creator>
<dc:creator>Liisa Byberg</dc:creator>
<dc:creator>John A Baron</dc:creator>
<dc:creator>Lars Lind</dc:creator>
<dc:creator>Karl Michaëlsson</dc:creator>
<dc:creator>Susanna C Larsson</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Plasma proteome and incident myocardial infarction: sex-specific differences</dc:title>
<dc:identifier>pmid:39397782</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae658</dc:identifier>
</item>
<item>
<title>Steps towards curing Yentl syndrome: appraising sex differences in circulating proteins and incident myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39397778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 14:ehae657. doi: 10.1093/eurheartj/ehae657. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39397778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39397778</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae657>10.1093/eurheartj/ehae657</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39397778</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Anna K Barton</dc:creator>
<dc:creator>Emily S Lau</dc:creator>
<dc:creator>Martha Gulati</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Steps towards curing Yentl syndrome: appraising sex differences in circulating proteins and incident myocardial infarction</dc:title>
<dc:identifier>pmid:39397778</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae657</dc:identifier>
</item>
<item>
<title>Atrioventricular node ablation for atrial fibrillation in the era of conduction system pacing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39397777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>Despite key advances in catheter-based treatments, the management of persistent atrial fibrillation (AF) remains a therapeutic challenge in a significant subset of patients. While success rates have improved with repeat AF ablation procedures and the concurrent use of antiarrhythmic drugs, the likelihood of maintaining sinus rhythm during long-term follow-up is still limited. Atrioventricular node ablation (AVNA) has returned as a valuable treatment option given the recent developments in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 14:ehae656. doi: 10.1093/eurheartj/ehae656. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite key advances in catheter-based treatments, the management of persistent atrial fibrillation (AF) remains a therapeutic challenge in a significant subset of patients. While success rates have improved with repeat AF ablation procedures and the concurrent use of antiarrhythmic drugs, the likelihood of maintaining sinus rhythm during long-term follow-up is still limited. Atrioventricular node ablation (AVNA) has returned as a valuable treatment option given the recent developments in cardiac pacing. With the advent of conduction system pacing, AVNA has seen a revival where pacing-induced cardiomyopathy after AVNA is felt to be overcome. This review will discuss the role of permanent pacemaker implantation and AVNA for AF management in this new era of conduction system pacing. Specifically, this review will discuss the haemodynamic consequences of AF and the mechanisms through which 'pace-and-ablate therapy' enhances outcomes, analyse historical and more recent literature across various pacing methods, and work to identify patient groups that may benefit from earlier implementation of this approach.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39397777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39397777</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae656>10.1093/eurheartj/ehae656</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39397777</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jacqueline Joza</dc:creator>
<dc:creator>Haran Burri</dc:creator>
<dc:creator>Jason G Andrade</dc:creator>
<dc:creator>Dominik Linz</dc:creator>
<dc:creator>Kenneth A Ellenbogen</dc:creator>
<dc:creator>Kevin Vernooy</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrioventricular node ablation for atrial fibrillation in the era of conduction system pacing</dc:title>
<dc:identifier>pmid:39397777</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae656</dc:identifier>
</item>
<item>
<title>Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39397661/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>Cardiac arrhythmias are commonly noted in patients during infections with and recovery from COVID-19. Arrhythmic manifestations span the spectrum of innocuous and benign to life-threatening and deadly. Various pathophysiological mechanisms have been proposed. Debate continues on the impact of incident and exacerbated arrhythmias on the acute and chronic (recovery) phase of the illness. COVID-19 and COVID-19 vaccine-associated myocardial inflammation and autonomic disruption remain concerns. As...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 14. doi: 10.1161/CIR.0000000000001290. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiac arrhythmias are commonly noted in patients during infections with and recovery from COVID-19. Arrhythmic manifestations span the spectrum of innocuous and benign to life-threatening and deadly. Various pathophysiological mechanisms have been proposed. Debate continues on the impact of incident and exacerbated arrhythmias on the acute and chronic (recovery) phase of the illness. COVID-19 and COVID-19 vaccine-associated myocardial inflammation and autonomic disruption remain concerns. As the pandemic has transformed to an endemic, with discovery of new SARS-CoV-2 variants, updated vaccines, and potent antiviral drugs, vigilance for COVID-19-associated arrhythmic and dysautonomic manifestations remains. The objective of this American Heart Association scientific statement is to review the available evidence on the epidemiology, pathophysiology, clinical presentation, and management of cardiac arrhythmias and autonomic dysfunction in patients infected with and recovering from COVID-19 and to provide evidence-based guidance. The writing committee's consensus on implications for clinical practice, gaps in knowledge, and directions for future research are highlighted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39397661/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39397661</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001290>10.1161/CIR.0000000000001290</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39397661</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Rakesh Gopinathannair</dc:creator>
<dc:creator>Brian Olshansky</dc:creator>
<dc:creator>Mina K Chung</dc:creator>
<dc:creator>Steve Gordon</dc:creator>
<dc:creator>Jose A Joglar</dc:creator>
<dc:creator>Gregory M Marcus</dc:creator>
<dc:creator>Philip L Mar</dc:creator>
<dc:creator>Andrea M Russo</dc:creator>
<dc:creator>Uma N Srivatsa</dc:creator>
<dc:creator>Elaine Y Wan</dc:creator>
<dc:creator>American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Genomic and Precision Medicine; and Council on Hypertension</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39397661</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001290</dc:identifier>
</item>
<item>
<title>The Effect of Teleprehabilitation on Adverse Events After Elective Cardiac Surgery: A Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39396714/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Multimodal personalized teleprehabilitation resulted in a clinically relevant and statistically significant reduction of the primary endpoint in patients undergoing cardiac surgery.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8:S0735-1097(24)09919-4. doi: 10.1016/j.jacc.2024.10.064. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients scheduled for cardiac surgery and procedures often present with modifiable risk factors for adverse perioperative outcomes. Prehabilitation has shown potential to enhance mental and physical fitness however, its effect on clinical cardiovascular endpoints in this population has not been studied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The current trial was designed to evaluate the effect of a personalized multimodal teleprehabilitation on the incidence of composite endpoint on major adverse cardiovascular events (MACE) in patients scheduled for elective cardiac surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a multicentre randomized controlled trial, 394 patients awaiting elective cardiac surgery and procedures were enrolled. Of these, 197 patients were randomized to an online multimodal personalized teleprehabilitation program through shared-decision making by a multidisciplinary team, and 197 were assigned to a control group. The primary outcome was MACE, (i.e., cardiovascular death, myocardial infarction, stroke, hospitalization for heart failure or other life-threatening cardiac events, and earlier or repeated intervention), as measured from the randomization until 1-year postoperatively. All events were adjudicated by a blinded event committee. Secondary outcomes included length of hospital stay, postoperative complications, quality of life, adherence to the program, and effect on the incidence of modifiable risk factors. Sensitivity analyses of the primary outcome were conducted adjusting for baseline characteristics to evaluate the consistency of treatment effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From randomization until one year postoperatively, the primary endpoint occurred in 33 patients (16.8%) in the teleprehabilitation group and 50 patients (25.5%) in the control group (difference 8.8%; 95% confidence interval (CI) 0.7 to 16.8; P=0.032). This difference was primarily driven by a reduction in hospitalizations and the sensitivity analyses showed that treatment effect was mainly in the patients undergoing a cardiac surgery rather than transcatheter procedures with adjusted odds ratio of 0.54 (95% CI, 0.30-0.96; P = 0.035). Teleprehabilitation also reduced the incidence of active smokers, elevated pulmonary risk scores, and elevated depression scores. There was no significant difference in postoperative length of hospital stay, occurrence of postoperative complications, physical fitness, incidence of obesity, or malnutrition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Multimodal personalized teleprehabilitation resulted in a clinically relevant and statistically significant reduction of the primary endpoint in patients undergoing cardiac surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov (NCT04393636).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39396714/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39396714</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.064>10.1016/j.jacc.2024.10.064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39396714</guid>
<pubDate>Sun, 13 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Bart Scheenstra</dc:creator>
<dc:creator>Lieke van Susante</dc:creator>
<dc:creator>Bart C Bongers</dc:creator>
<dc:creator>Ton Lenssen</dc:creator>
<dc:creator>Henriette Knols</dc:creator>
<dc:creator>Sander van Kuijk</dc:creator>
<dc:creator>Maxime Nieman</dc:creator>
<dc:creator>Jos Maessen</dc:creator>
<dc:creator>Arnoud Van't Hof</dc:creator>
<dc:creator>Peyman Sardari Nia</dc:creator>
<dc:creator>Digital Cardiac Counseling (DCC) Trial investigators</dc:creator>
<dc:date>2024-10-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Effect of Teleprehabilitation on Adverse Events After Elective Cardiac Surgery: A Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:39396714</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.064</dc:identifier>
</item>
<item>
<title>Optimizing AHA/ACC Guidelines for the Digital Age: Guidelines in Evolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39396366/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 4:S0735-1097(24)07844-6. doi: 10.1016/j.jacc.2024.07.007. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39396366/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39396366</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.007>10.1016/j.jacc.2024.07.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39396366</guid>
<pubDate>Sun, 13 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Catherine M Otto</dc:creator>
<dc:creator>Mariell Jessup</dc:creator>
<dc:creator>Richard J Kovacs</dc:creator>
<dc:creator>Joshua A Beckman</dc:creator>
<dc:date>2024-10-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Optimizing AHA/ACC Guidelines for the Digital Age: Guidelines in Evolution</dc:title>
<dc:identifier>pmid:39396366</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.007</dc:identifier>
</item>
<item>
<title>Structural basis of respiratory complex adaptation to cold temperatures</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39395414/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>In response to cold, mammals activate brown fat for respiratory-dependent thermogenesis reliant on the electron transport chain. Yet, the structural basis of respiratory complex adaptation upon cold exposure remains elusive. Herein, we combined thermoregulatory physiology and cryoelectron microscopy (cryo-EM) to study endogenous respiratory supercomplexes from mice exposed to different temperatures. A cold-induced conformation of CI:III(2) (termed type 2) supercomplex was identified with a ∼25°...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 3:S0092-8674(24)01087-0. doi: 10.1016/j.cell.2024.09.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In response to cold, mammals activate brown fat for respiratory-dependent thermogenesis reliant on the electron transport chain. Yet, the structural basis of respiratory complex adaptation upon cold exposure remains elusive. Herein, we combined thermoregulatory physiology and cryoelectron microscopy (cryo-EM) to study endogenous respiratory supercomplexes from mice exposed to different temperatures. A cold-induced conformation of CI:III<sub>2</sub> (termed type 2) supercomplex was identified with a ∼25° rotation of CIII<sub>2</sub> around its inter-dimer axis, shortening inter-complex Q exchange space, and exhibiting catalytic states that favor electron transfer. Large-scale supercomplex simulations in mitochondrial membranes reveal how lipid-protein arrangements stabilize type 2 complexes to enhance catalytic activity. Together, our cryo-EM studies, multiscale simulations, and biochemical analyses unveil the thermoregulatory mechanisms and dynamics of increased respiratory capacity in brown fat at the structural and energetic level.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39395414/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39395414</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.029>10.1016/j.cell.2024.09.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39395414</guid>
<pubDate>Sat, 12 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Young-Cheul Shin</dc:creator>
<dc:creator>Pedro Latorre-Muro</dc:creator>
<dc:creator>Amina Djurabekova</dc:creator>
<dc:creator>Oleksii Zdorevskyi</dc:creator>
<dc:creator>Christopher F Bennett</dc:creator>
<dc:creator>Nils Burger</dc:creator>
<dc:creator>Kangkang Song</dc:creator>
<dc:creator>Chen Xu</dc:creator>
<dc:creator>Joao A Paulo</dc:creator>
<dc:creator>Steven P Gygi</dc:creator>
<dc:creator>Vivek Sharma</dc:creator>
<dc:creator>Maofu Liao</dc:creator>
<dc:creator>Pere Puigserver</dc:creator>
<dc:date>2024-10-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structural basis of respiratory complex adaptation to cold temperatures</dc:title>
<dc:identifier>pmid:39395414</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.029</dc:identifier>
</item>
<item>
<title>Genome integrity sensing by the broad-spectrum Hachiman antiphage defense complex</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39395413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>Hachiman is a broad-spectrum antiphage defense system of unknown function. We show here that Hachiman is a heterodimeric nuclease-helicase complex, HamAB. HamA, previously a protein of unknown function, is the effector nuclease. HamB is the sensor helicase. HamB constrains HamA activity during surveillance of intact double-stranded DNA (dsDNA). When the HamAB complex detects DNA damage, HamB helicase activity activates HamA, unleashing nuclease activity. Hachiman activation degrades all DNA in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 3:S0092-8674(24)01068-7. doi: 10.1016/j.cell.2024.09.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hachiman is a broad-spectrum antiphage defense system of unknown function. We show here that Hachiman is a heterodimeric nuclease-helicase complex, HamAB. HamA, previously a protein of unknown function, is the effector nuclease. HamB is the sensor helicase. HamB constrains HamA activity during surveillance of intact double-stranded DNA (dsDNA). When the HamAB complex detects DNA damage, HamB helicase activity activates HamA, unleashing nuclease activity. Hachiman activation degrades all DNA in the cell, creating "phantom" cells devoid of both phage and host DNA. We demonstrate Hachiman activation in the absence of phage by treatment with DNA-damaging agents, suggesting that Hachiman responds to aberrant DNA states. Phylogenetic similarities between the Hachiman helicase and enzymes from eukaryotes and archaea suggest deep functional symmetries with other important helicases across domains of life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39395413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39395413</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.020>10.1016/j.cell.2024.09.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39395413</guid>
<pubDate>Sat, 12 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Owen T Tuck</dc:creator>
<dc:creator>Benjamin A Adler</dc:creator>
<dc:creator>Emily G Armbruster</dc:creator>
<dc:creator>Arushi Lahiri</dc:creator>
<dc:creator>Jason J Hu</dc:creator>
<dc:creator>Julia Zhou</dc:creator>
<dc:creator>Joe Pogliano</dc:creator>
<dc:creator>Jennifer A Doudna</dc:creator>
<dc:date>2024-10-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Genome integrity sensing by the broad-spectrum Hachiman antiphage defense complex</dc:title>
<dc:identifier>pmid:39395413</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.020</dc:identifier>
</item>
<item>
<title>Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39394525/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>Dilated cardiomyopathy (DCM) is a complex disease with multiple causes and various pathogenic mechanisms. Despite improvements in the prognosis of patients with DCM in the past decade, this condition remains a leading cause of heart failure and premature death. Conventional treatment for DCM is based on the foundational therapies for heart failure with reduced ejection fraction. However, increasingly, attention is being directed towards individualized treatments and precision medicine. The...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 11. doi: 10.1038/s41569-024-01074-2. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Dilated cardiomyopathy (DCM) is a complex disease with multiple causes and various pathogenic mechanisms. Despite improvements in the prognosis of patients with DCM in the past decade, this condition remains a leading cause of heart failure and premature death. Conventional treatment for DCM is based on the foundational therapies for heart failure with reduced ejection fraction. However, increasingly, attention is being directed towards individualized treatments and precision medicine. The ability to confirm genetic causality is gradually being complemented by an increased understanding of genotype-phenotype correlations. Non-genetic factors also influence the onset of DCM, and growing evidence links genetic background with concomitant non-genetic triggers or precipitating factors, increasing the extreme complexity of the pathophysiology of DCM. This Review covers the spectrum of pathophysiological mechanisms in DCM, from monogenic causes to the coexistence of genetic abnormalities and triggering environmental factors (the 'two-hit' hypothesis). The roles of common genetic variants in the general population and of gene modifiers in disease onset and progression are also discussed. Finally, areas for future research are highlighted, particularly novel therapies, such as small molecules, RNA and gene therapy, and measures for the prevention of arrhythmic death.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39394525/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39394525</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01074-2>10.1038/s41569-024-01074-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39394525</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Marta Gigli</dc:creator>
<dc:creator>Davide Stolfo</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine</dc:title>
<dc:identifier>pmid:39394525</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01074-2</dc:identifier>
</item>
<item>
<title>Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39394524/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>Over the past 50 years, the number and invasiveness of percutaneous cardiovascular procedures globally have increased substantially. However, cardiovascular interventions are inherently associated with a risk of acute brain injury, both periprocedurally and postprocedurally, which impairs medical outcomes and increases health-care costs. Current international clinical guidelines generally do not cover the area of acute brain injury related to cardiovascular invasive procedures. In this...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 11. doi: 10.1038/s41569-024-01076-0. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Over the past 50 years, the number and invasiveness of percutaneous cardiovascular procedures globally have increased substantially. However, cardiovascular interventions are inherently associated with a risk of acute brain injury, both periprocedurally and postprocedurally, which impairs medical outcomes and increases health-care costs. Current international clinical guidelines generally do not cover the area of acute brain injury related to cardiovascular invasive procedures. In this international Consensus Statement, we compile the available knowledge (including data on prevalence, pathophysiology, risk factors, clinical presentation and management) to formulate consensus recommendations on the prevention, diagnosis and treatment of acute brain injury caused by cardiovascular interventions. We also identify knowledge gaps and possible future directions in clinical research into acute brain injury related to cardiovascular interventions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39394524/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39394524</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01076-0>10.1038/s41569-024-01076-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39394524</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Radosław Lenarczyk</dc:creator>
<dc:creator>Marco Proietti</dc:creator>
<dc:creator>Jan F Scheitz</dc:creator>
<dc:creator>Dipen Shah</dc:creator>
<dc:creator>Eberhard Siebert</dc:creator>
<dc:creator>Diana A Gorog</dc:creator>
<dc:creator>Jacek Kowalczyk</dc:creator>
<dc:creator>Nikolaos Bonaros</dc:creator>
<dc:creator>George Ntaios</dc:creator>
<dc:creator>Wolfram Doehner</dc:creator>
<dc:creator>Nicolas M Van Mieghem</dc:creator>
<dc:creator>Sandor Nardai</dc:creator>
<dc:creator>Jan Kovac</dc:creator>
<dc:creator>Roland Fiszer</dc:creator>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Eliano Navarese</dc:creator>
<dc:creator>Sergio Castrejón</dc:creator>
<dc:creator>Andrea Rubboli</dc:creator>
<dc:creator>José Miguel Rivera-Caravaca</dc:creator>
<dc:creator>Alaide Chieffo</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures</dc:title>
<dc:identifier>pmid:39394524</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01076-0</dc:identifier>
</item>
<item>
<title>Correction to: Great debate: myocardial infarction after cardiac surgery must be redefined</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392465/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 11:ehae734. doi: 10.1093/eurheartj/ehae734. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392465/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39392465</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae734>10.1093/eurheartj/ehae734</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392465</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Great debate: myocardial infarction after cardiac surgery must be redefined</dc:title>
<dc:identifier>pmid:39392465</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae734</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: FINEARTS-HF supports the role of aldosterone antagonism in the management of heart failure with mildly reduced or preserved ejection fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 11:ehae679. doi: 10.1093/eurheartj/ehae679. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39392246</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae679>10.1093/eurheartj/ehae679</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392246</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Massimo Volpe</dc:creator>
<dc:creator>Leonarda Galiuto</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: FINEARTS-HF supports the role of aldosterone antagonism in the management of heart failure with mildly reduced or preserved ejection fraction</dc:title>
<dc:identifier>pmid:39392246</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae679</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: is MATTERHORN a game changer for secondary mitral regurgitation? Still climbing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392244/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014224556&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 11:ehae650. doi: 10.1093/eurheartj/ehae650. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392244/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014224556&v=2.18.0.post9+e462414">39392244</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae650>10.1093/eurheartj/ehae650</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392244</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: is MATTERHORN a game changer for secondary mitral regurgitation? Still climbing</dc:title>
<dc:identifier>pmid:39392244</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae650</dc:identifier>
</item>





























</channel>
</rss>